Dr. Reddy's Launches First-to-Market Generic Bosulif® (Bosutinib) in US with 180-Day Exclusivity
RDY is trading near its 52-week low of $12.185 (9.2% above the low).
Summary
Dr. Reddy's has launched the first generic version of Bosulif® (Bosutinib) in the U.S., securing 180 days of market exclusivity for a drug with over $250 million in annual sales.
Key Events · Product Development and Regulatory · RDY
-
First-to-Market Generic Launch
Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.
-
180-Day Market Exclusivity
The company achieved "first-to-file" status, granting it 180 days of generic drug exclusivity for this product strength in the U.S.
-
Significant Market Opportunity
The branded drug, Bosulif® 400mg, recorded approximately $253.8 million in U.S. sales over the last 12 months, representing a substantial revenue opportunity for Dr. Reddy's.
-
Oncology Portfolio Expansion
This launch expands Dr. Reddy's oncology portfolio, reinforcing its commitment to providing affordable, high-quality medicines in a critical therapeutic area.
Analysis · RDY · Life Sciences
Dr. Reddy's Laboratories has launched the first generic equivalent of Bosulif® (Bosutinib Tablets 400mg) in the United States. This launch is significant because the company secured "first-to-file" status, granting it 180 days of generic drug exclusivity for this strength. The branded drug had U.S. sales of approximately $253.8 million in the past year, indicating a substantial market opportunity for Dr. Reddy's during its exclusivity period. This strategic entry into the oncology market is a positive development, especially following recent reports of profit and revenue declines in North America.
At the time of this filing, RDY was trading at $13.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.2B. The 52-week trading range was $12.19 to $16.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.